Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 3, 2026, 6:45 AM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2041–2064 of 21,220 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Immunity Disorders Clear all
Completed Not applicable Interventional

Retrovir Capsules in the Treatment of HIV-Infected Patients in Renal Failure

NCT00002047
View directory record Official record
Conditions
HIV Infections, Kidney Failure, Chronic
Interventions
Zidovudine
Drug
Lead sponsor
Glaxo Wellcome
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Nov 3, 2026, 6:45 AM EST
Terminated Phase 2 Interventional Results available

Study Evaluating the Safety and Effects of MN-221 in Subjects Experiencing an Acute Exacerbation of Asthma

NCT00683449
View directory record Official record
Conditions
Asthma, Status Asthmaticus
Interventions
Dose Group 1, MN-221 placebo, Dose Group 2, Dose Group 3
Drug
Lead sponsor
MediciNova
Industry
Eligibility
18 Years to 55 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
9
States / cities
Phoenix, Arizona • Los Angeles, California • Sylmar, California + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2011 · Synced Nov 3, 2026, 6:45 AM EST
Completed Not applicable Interventional Results available

Study to Evaluate the Effect of Nicotinamide Riboside on Immunity

NCT02812238
View directory record Official record
Conditions
Atherosclerosis, Diabetes, Coronary Artery Disease
Interventions
Nicotinamide riboside (NR), Placebo
Dietary Supplement · Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years to 39 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 17, 2019 · Synced Nov 3, 2026, 6:45 AM EST
Completed Phase 2 Interventional Results available

Lenalidomide and Ofatumumab in Treating Participants With Previously Treated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

NCT01002755
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia, Fatigue, Fever, Hypogammaglobulinemia, Lymphadenopathy, Lymphocytosis, Night Sweats, Paraproteinemia, Small Lymphocytic Lymphoma, Thrombocytopenia
Interventions
Lenalidomide, Ofatumumab
Drug · Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
19 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 7, 2019 · Synced Nov 3, 2026, 6:45 AM EST
Completed Phase 2 Interventional

Bone Marrow Transplantation in Treating Patients With Hematologic Cancer

NCT00005804
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Precancerous/Nonmalignant Condition, Small Intestine Cancer
Interventions
cyclophosphamide, allogeneic bone marrow transplantation, radiation therapy
Drug · Procedure · Radiation
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
Up to 50 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2002
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 2, 2010 · Synced Nov 3, 2026, 6:45 AM EST
Terminated Not applicable Interventional

Memory and Attention Problems in Lupus: New Treatment Trial With Modafinil

NCT00297284
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Modafinil
Drug
Lead sponsor
Hospital for Special Surgery, New York
Other
Eligibility
18 Years to 60 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 28, 2009 · Synced Nov 3, 2026, 6:45 AM EST
Completed No phase listed Observational

Factors Predicting Persistence of Oncogenic HPV and Cervical Dysplasia in HIV Infected Kenyan Women

NCT04045652
View directory record Official record
Conditions
HIV/AIDS, Cervical Dysplasia, HIV Infections
Interventions
Not listed
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
223 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jul 17, 2024 · Synced Nov 3, 2026, 6:45 AM EST
Terminated Phase 3 Interventional Results available

Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer

NCT01132547
View directory record Official record
Conditions
Cancer
Interventions
cyproheptadine hydrochloride, placebo
Drug · Other
Lead sponsor
University of South Florida
Other
Eligibility
2 Years to 21 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
14
States / cities
Long Beach, California • Hartford, Connecticut • Wilmington, Delaware + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2015 · Synced Nov 3, 2026, 6:45 AM EST
Completed No phase listed Observational Accepts healthy volunteers

Wearable Skin Sensors to Assess Nocturnal Scratch Behavior

NCT03770858
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Crisaborole, Scratch sensor
Drug · Device
Lead sponsor
Northwestern University
Other
Eligibility
2 Years and older
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 13, 2023 · Synced Nov 3, 2026, 6:45 AM EST
Completed Not applicable Interventional Accepts healthy volunteers

Gilenya's Impact on Cognitive Function and Thalamic Volumes

NCT03243721
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
7T MRI, Neurocognitive testing
Diagnostic Test
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 50 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 5, 2021 · Synced Nov 3, 2026, 6:45 AM EST
Completed Phase 4 Interventional Results available

The Impact of Omega Three Fatty Acids on Vascular Function in HIV

NCT01041521
View directory record Official record
Conditions
High Triglyceride Level, HIV Infection
Interventions
Lovaza
Drug
Lead sponsor
Tufts University
Other
Eligibility
18 Years and older
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 11, 2020 · Synced Nov 3, 2026, 6:45 AM EST
Recruiting Phase 1Phase 2 Interventional

A First-in-Human Trial of DS3790a in Participants With Hematological Malignancies

NCT07220616
View directory record Official record
Conditions
Hematological Malignancies, B-cell Non-Hodgkin Lymphoma
Interventions
DS3790a, Combination drug
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
420 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Nov 3, 2026, 6:45 AM EST
Enrolling by invitation No phase listed Observational

Leukapheresis for CAR or Adoptive Cell Therapy Manufacturing

NCT03226704
View directory record Official record
Conditions
Leukemia, Lymphoma, Acute Lymphoblastic Leukemia, Diffuse Large B Cell Lymphoma, Non-Hodgkin's Lymphoma
Interventions
Leukapheresis
Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
3 Years to 65 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2030
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 29, 2026 · Synced Nov 3, 2026, 6:45 AM EST
Completed Phase 2 Interventional Results available

Study of Bortezomib and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma

NCT01478048
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Elotuzumab, Bortezomib, Dexamethasone
Biological · Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
185 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
42
States / cities
Corona, California • Long Beach, California • Los Angeles, California + 35 more
Source: ClinicalTrials.gov public record
Updated May 21, 2018 · Synced Nov 3, 2026, 6:45 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

Study of a Potential Preventive Vaccine Against HIV in Healthy Volunteers

NCT00545987
View directory record Official record
Conditions
HIV Infections
Interventions
TriGrid™ Delivery System, conventional intramuscular injection
Device
Lead sponsor
Rockefeller University
Other
Eligibility
18 Years to 60 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 5, 2011 · Synced Nov 3, 2026, 6:45 AM EST
Completed Phase 1 Interventional Results available

A Study of Obinutuzumab (GA101; RO5072759) in Combination With Chemotherapy in Participants With Previously Untreated Chronic Lymphocytic Leukemia (CLL) (GALTON)

NCT01300247
View directory record Official record
Conditions
Lymphocytic Leukemia, Chronic
Interventions
Fludarabine, Obinutuzumab, Bendamustine, Cyclophosphamide
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
18
States / cities
Huntsville, Alabama • Duarte, California • La Jolla, California + 15 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2017 · Synced Nov 3, 2026, 6:45 AM EST
Completed No phase listed Observational

Adiposity and Airway Inflammation in HIV-Associated Airway Disease

NCT02975258
View directory record Official record
Conditions
Asthma, HIV, Adiposity
Interventions
Blood draw, Questionnaires, Spirometry, Methacholine challenge test, Quantitative CT scans, Urine pregnancy test, Adipose biopsy, Exhaled nitric oxide measurement
Procedure · Other · Radiation
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 80 Years
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 13, 2017 · Synced Nov 3, 2026, 6:45 AM EST
Active, not recruiting Phase 2 Interventional

VIR-2218 and Peginterferon Alfa-2a for Chronic Hepatitis B

NCT06092333
View directory record Official record
Conditions
Chronic Hepatitis B
Interventions
VIR-2218 and peginterferon alfa-2a
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Nov 3, 2026, 6:45 AM EST
Completed Phase 1Phase 2 Interventional

Safety and Efficacy Study of Imexon for Treatment of Multiple Myeloma Patients

NCT00327249
View directory record Official record
Conditions
Multiple Myeloma
Interventions
imexon
Drug
Lead sponsor
AmpliMed Corporation
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
2
States / cities
Little Rock, Arkansas • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 11, 2009 · Synced Nov 3, 2026, 6:45 AM EST
Not listed Phase 4 Interventional

Buprenorphine and Integrated HIV Care Evaluation

NCT00124358
View directory record Official record
Conditions
Opioid-Related Disorders, HIV Infections, AIDS
Interventions
Buprenorphine, Integrated HIV care and office-based opioid dependence treatment
Drug · Behavioral
Lead sponsor
The New York Academy of Medicine
Other
Eligibility
18 Years and older
Enrollment
1,350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
10
States / cities
Tucson, Arizona • Oakland, California • San Francisco, California + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2007 · Synced Nov 3, 2026, 6:45 AM EST
Completed Not applicable Interventional Accepts healthy volunteers

Telemedicine for Adolescents With Insulin-dependent Diabetes

NCT02155855
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Telemedicine, Control
Other
Lead sponsor
Texas Tech University Health Sciences Center
Other
Eligibility
10 Years to 18 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Lubbock, Texas
Source: ClinicalTrials.gov public record
Updated Dec 10, 2019 · Synced Nov 3, 2026, 6:45 AM EST
Completed No phase listed Observational

Pulmonary Function in Patients With Hodgkin's Disease Receiving Bleomycin-Based Chemotherapy

NCT00165438
View directory record Official record
Conditions
Hodgkin's Disease
Interventions
Pulmonary Function Tests, CAT Scan
Procedure
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2010
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 20, 2012 · Synced Nov 3, 2026, 6:45 AM EST
Completed Phase 4 Interventional

Safety and Efficacy of Pimecrolimus Cream 1% in Mild to Moderate Head and Neck Atopic Dermatitis (AD) Patients

NCT00121316
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Pimecrolimus, Placebo
Drug
Lead sponsor
Novartis
Industry
Eligibility
12 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
0
States / cities
Not listed
Source: ClinicalTrials.gov public record
Updated Jan 15, 2008 · Synced Nov 3, 2026, 6:45 AM EST
Completed Phase 2 Interventional Results available

A Phase II Trial of Ofatumumab in Subjects With Waldenstrom's Macroglobulinemia

NCT00811733
View directory record Official record
Conditions
Waldenstrom Macroglobulinaemia
Interventions
Ofatumumab
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
7
States / cities
Los Angeles, California • Stanford, California • Rochester, Minnesota + 4 more
Source: ClinicalTrials.gov public record
Updated May 30, 2017 · Synced Nov 3, 2026, 6:45 AM EST